Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

被引：16
|
作者：
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-149024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
79
引用
收藏
页数：9
相关论文
共 50 条
  • [31] Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
    Loiseau, Herve Avet
    Sonneveld, Pieter
    Moreau, Philippe
    Offner, Fritz
    van der Velden, Vincent H. J.
    Caillot, Denis
    Hulin, Cyrille
    Arnulf, Bertrand
    Corre, Jill
    Mohty, Mohamad
    Karlin, Lionel
    Lambert, Jerome
    Macro, Margaret
    Perrot, Aurore
    Levin, Mark-David
    Klein, Saskia K.
    Stoppa, Anne-Marie
    Delforge, Michel
    Zweegman, Sonja
    Jie, Kon-Siong
    Van De Donk, Niels W. C. J.
    Krevvata, Maria
    Rigat, Fabio
    Yang, Shiyi
    Vanquickelberghe, Veronique
    de Boer, Carla
    Kampfenkel, Tobias
    Vermeulen, Jessica
    Wuilleme, Soraya
    Broyl, Annemiek
    Bene, Marie C.
    BLOOD, 2021, 138
  • [32] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
    Nishimura, Noriko
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nagata, Yasuyuki
    Okaduka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215
  • [33] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTD) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-Risk Patients in Cassiopeia
    Sonneveld, Pieter
    Attal, Michel
    Perrot, Aurore
    Hulin, Cyrille
    Caillot, Denis
    Facon, Thierry
    Leleu, Xavier
    Belhadj, Karim
    Karlin, Lionel
    Benboubker, Lotfi
    Levin, Mark-David
    Minnema, Monique C.
    Westerman, Matthijs
    Delforge, Michel
    Zweegman, Sonja
    Pei, Lixia
    de Boer, Carla
    Vanquickelberghe, Veronique
    Kampfenkel, Tobias
    Moreau, Philippe
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 124 - 126
  • [34] Daratumumab (DARA) plus Bortezomib/ Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study
    Moreau, Philippe
    Hulin, Cyrille
    Perrot, Aurore
    Arnulf, Bertrand
    Belhadj, Karim
    Benboubker, Lotfi
    Zweegman, Sonja
    Caillon, Helene
    Caillot, Denis
    Avet-Loiseau, Herve
    Delforge, Michel
    Dejoie, Thomas
    Facon, Thierry
    Sonntag, Cecile
    Fontan, Jean
    Mohty, Mohamad
    Jie, Kon-Siong
    Karlin, Lionel
    Kuhnowski, Frederique
    Lambert, Jerome
    Leleu, Xavier
    Macro, Margaret
    Orsini-Piocelle, Frederique
    Roussel, Murielle
    de Colella, Jean Marc Schiano
    van de Donk, Niels W. C. J.
    Wuilleme, Soraya
    Broijl, Annemiek
    Touzeau, Cyrille
    Tiab, Mourad
    Marolleau, Jean-Pierre
    Meuleman, Nathalie
    Vekemans, Marie-Christiane
    Westerman, Matthijs
    Klein, Saskia K.
    Levin, Mark-David
    Offner, Fritz
    Escoffre-Barbe, Martine
    Eveillard, Jean-Richard
    Garidi, Reda
    Hua, Winnie
    Wang, Jianping
    Tuozzo, Alba
    de Boer, Carla J.
    Rowe, Melissa
    Vanquickelberghe, Veronique
    Carson, Robin
    Vermeulen, Jessica
    Corre, Jill
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S560 - S561
  • [35] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    Nashimoto, Junichiro
    Uto, Yui
    Sato, Kota
    Miyazaki, Kanji
    Ogura, Mizuki
    Yoshiki, Yumiko
    Abe, Yu
    Tsukada, Nobuhiro
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
  • [36] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
    Bhutani, Manisha
    Robinson, Myra
    Atrash, Shebli
    Watts, Nicole
    Paul, Barry
    Chhabra, Saurabh
    Korde, Neha
    Begic, Xhevahire
    Foureau, David M.
    Chung, David J.
    Pineda-Roman, Mauricio
    Koya, Brinda
    Varga, Cindy
    Ai, Jing
    Daniels, Natonya
    Norek, Sarah
    Sutton, Sara A.
    Anderson, Michelle B.
    Jewell, Ashley N.
    Eldridge, Paul W.
    Acampora, Donna
    Symanowski, James T.
    Costa, Luciano J.
    Usmani, Saad
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 4393 - 4395
  • [37] Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
    Sonneveld, Pieter
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Quach, Hang
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    Nijhof, Inger S.
    van de Donk, Niels W. C. J.
    Katodritou, Eirini
    Schjesvold, Fredrik
    Sureda Balari, Anna
    Rosinol, Laura
    Delforge, Michel
    Roeloffzen, Wilfried
    Driessen, Christoph
    Vangsted, Annette
    Einsele, Hermann
    Spencer, Andrew
    Hajek, Roman
    Jurczyszyn, Artur
    Lonergan, Sarah
    Liu, Yanfang
    Wang, Jianping
    Vieyra, Diego
    van Brummelen, Emilie M. J.
    Vanquickelberghe, Veronique
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Blade, Joan
    Boccadoro, Mario
    Rodriguez-Otero, Paula
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S550 - S551
  • [38] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia
    Bahlis, Nizar
    Facon, Thierry
    Usmani, Saad Z.
    Kumar, Shaji K.
    Plesner, Torben
    Orlowski, Robert Z.
    Touzeau, Cyrille
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael E.
    Venner, Christopher P.
    Weisel, Katja C.
    Krevvata, Maria
    Pei, Huiling
    Wang, Jianping
    Van Rampelbergh, Rian
    Ukropec, Jon
    Uhlar, Clarissa M.
    Kobos, Rachel
    Perrot, Aurore
    BLOOD, 2019, 134
  • [39] Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
    Silbermann, Rebecca
    Laubach, Jacob
    Kaufman, Jonathan L.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Costa, Luciano J.
    Anderson, Larry D.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Gries, Katharine S.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Richardson, Paul G.
    Usmani, Saad
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 1146 - 1149
  • [40] Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
    Sborov, Douglas W.
    Baljevic, Muhamed
    Reeves, Brandi
    Laubach, Jacob
    Efebera, Yvonne A.
    Rodriguez, Cesar
    Costa, Luciano J.
    Chari, Ajai
    Silbermann, Rebecca
    Holstein, Sarah A.
    Anderson, Larry D., Jr.
    Kaufman, Jonathan L.
    Shah, Nina
    Pei, Huiling
    Patel, Sharmila
    Cortoos, Annelore
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Voorhees, Peter M.
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (03) : 355 - 365
12345